Lynparza则是一种“first-in-class"的PARP抑制剂，也是首个合成致死靶向治疗药物，用于靶向带有同源重组修复(HRR)缺陷的细胞/肿瘤(如携带BRCA1和/或BRCA2突变的细胞)。基于3期临床试验OlympiA的结果，Lynparza已在美国、欧盟、日本及许多其他国家和地区获批，用于治疗gBRCAm、HER2阴性高危早期乳腺癌。此外，它还获批在美国、欧盟、日本及许多其他国家和地区用于治疗gBRCAm、HER2阴性转移性乳腺癌。Lynparza is a "first-in-class" PARP inhibitor and the first targeted treatment that works through the concept of synthetic lethality, aimed at targeting cells/tumors with homologous recombination repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
According to the Zhito Finance APP, AstraZeneca (AZN.US) and Merck (MRK.US) announced the long-term results of the Phase 3 clinical trial OlympiA today. The study shows that the PARP inhibitor Lynparza (olaparib) significantly improves overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) in high-risk early breast cancer patients with germline BRCA mutations (gBRCAm) who are HER2-negative.
With a median follow-up of 6.1 years, in patients who have completed local treatment and standard neoadjuvant or adjuvant chemotherapy, Lynparza reduced the risk of death by 28% compared to placebo (HR=0.72; 95% CI: 0.56-0.93). Additionally, 87.5% of patients receiving Lynparza were still alive, while the survival rate for the placebo group was 83.2%.
Lynparza is a "first-in-class" PARP inhibitor and the first targeted treatment that works through the concept of synthetic lethality, aimed at targeting cells/tumors with homologous recombination repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations). Based on the results of the Phase 3 clinical trial OlympiA, Lynparza has been approved in the USA, European Union, Japan, and many Other countries and regions for the treatment of gBRCAm, HER2-negative high-risk early breast cancer. Furthermore, it has also been approved in the USA, European Union, Japan, and many Other countries and regions for the treatment of gBRCAm, HER2-negative metastatic breast cancer.
